Obupro (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride blocks voltage‑gated sodium channels on peripheral nerves in the ocular surface. By preventing sodium influx, it stops the generation and propagation of nerve impulses, resulting in a temporary loss of sensation that allows clinicians to perform eye procedures without discomfort.

The specific dose and frequency of Obupro are determined by the prescribing clinician based on the intended procedure. Typically, a single drop is applied to the conjunctival sac immediately before the examination or minor surgery, with the amount adjusted as needed for adequate anesthesia.

Safety data for Oxybuprocaine Hydrochloride during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Obupro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to Oxybuprocaine is proparacaine. Both provide rapid corneal anesthesia, but Oxybuprocaine typically has a slightly longer duration of action and may be preferred for procedures requiring a few extra minutes of numbness. Choice depends on clinician preference and patient tolerance.

Obupro should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from direct light, moisture and extreme temperatures. Do not freeze the solution, and keep it out of reach of children.

Obupro is applied as a sterile ophthalmic drop. The patient should look upward while a single drop is placed into the lower conjunctival sac. The eyelid may be gently closed for a few seconds to allow even distribution before the procedure begins.

Serious adverse events, though rare, include severe allergic reactions such as anaphylaxis, corneal ulceration or persistent epithelial defects, and significant ocular inflammation. Any signs of worsening pain, vision loss, or systemic symptoms should prompt immediate medical evaluation.

Obupro should be avoided in patients with known hypersensitivity to Oxybuprocaine or other ester‑type anesthetics, in eyes with active infection or severe epithelial damage, and in individuals where the risk of anesthesia outweighs the clinical benefit, as determined by the prescriber.